# A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

> **NCT00231829** · PHASE2 · TERMINATED · sponsor: **Mark H. Einstein** · enrollment: 23 (—)

## Conditions studied

- Uterine Cancer

## Interventions

- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00231829
- **Lead sponsor:** Mark H. Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 23 (—)
- **Why stopped:** Due to reported toxicity of Celecoxib at high doses
- **Last updated:** 2012-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00231829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00231829, "A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00231829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*